One class of medications, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, are at the forefront of the cardiovascular outcomes prevention discussion. The clinical data presented in this review indicate the potential cardiovascular benefits of SGLT-2 inhibitors in patients with CVD and its potential...
Sodium glucose cotransporter 2 inhibitors EMPA-REG OUTCOME [114•] n = 7020 T2D and CVD MACEa Empagliflozin versus placebo 0.86 (0.74–0.99) P < 0.001 non-inferiority, P = 0.04 superiority Genital infections, bone fractures. CANVAS and CANVAS-R [118] n = 4330 T2D/at...
Greco, A. Sodium-Glucose Cotransporter-2 Inhibitors: Elevating Standards in Cardiovascular Secondary Prevention. Am J Cardiovasc Drugs 24, 625–628 (2024). https://doi.org/10.1007/s40256-024-00666-0 Download citation Accepted03 July 2024 Published17 July 2024 Issue DateSeptember 2024 DOIhttps://...
Keywords:SGLT2 inhibitors;SGLT2i;Cardiovascular disease;Heart failure;Atherosclerotic cardiovascular disease;Diabetic kidney disease Core Tip:The new antidiabetic medication class sodium glucose cotransporter-2 inhibitors (SGLT-2i) are found to have remarkable cardiovascular (CV) benefits proven by multiple ...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have now been shown to prevent cardiovascular events, especially hospitalization for heart failure, in three large randomized clinical trials: EMPA-REG OUTCOME, the CANVAS program, and the DECLARE-TIMI58 trial. It is expected, therefore, that SGLT2...
Serum glucoseSodium‐glucose cotransporter‐2 (SGLT‐2)doi:10.1002/9781118682197.ch6Anthony H. BarnettBirmingham Heartlands Hospital University of Birmingham and Heart of England National Health Service Foundation Trust Birmingham, UKJenny GriceLe Prioldy, Bieuzy les Eaux, France...
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt...
Sodium glucose cotransporter type 2 inhibitors (SGLT‐2i) have a novel and unique mechanism of action. By inhibiting sodium and glucose reabsorption in the proximal tubule, SGLT‐2i result in a number of downstream effects, including glucosuria, weight loss, osmotic diuresis and natriuresis, ...
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels. In clinical trials, the risk of serious adverse events with SGLT2i has been low, but the saf...
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus Introduction Diabetes is a major public health problem, affecting approximately 10% of the population [1]. Type 2 diabetes mellitus (T2DM) is a chronic and complex metabolic disease [1,2,3]. T2DM is ...